22
Pulmonary tuberculosis DR. Yousef Noaimat MD.FCCP Consultant in pulmonary and internal medicine.

Pulmonary tuberculosis DR. Yousef Noaimat MD.FCCP Consultant in pulmonary and internal medicine

Embed Size (px)

Citation preview

Page 1: Pulmonary tuberculosis DR. Yousef Noaimat MD.FCCP Consultant in pulmonary and internal medicine

Pulmonary tuberculosis

DR. Yousef Noaimat MD.FCCPConsultant in pulmonary and

internal medicine.

Page 2: Pulmonary tuberculosis DR. Yousef Noaimat MD.FCCP Consultant in pulmonary and internal medicine

History

• Tubercular decay has been found in the spines of Egyptian mummies.

• Pictured: Egyptian mummy in the British Museum

Page 3: Pulmonary tuberculosis DR. Yousef Noaimat MD.FCCP Consultant in pulmonary and internal medicine

Epidemiology

• According to the World Health Organization (WHO), nearly 2 billion people—one third of the world's population—have been exposed to the tuberculosis pathogen

• Annually, 8 million people become ill with tuberculosis, and 2 million people die from the disease worldwide

Page 4: Pulmonary tuberculosis DR. Yousef Noaimat MD.FCCP Consultant in pulmonary and internal medicine

• World TB incidence. Cases per 100,000; Red => 300, orange = 200–300, yellow = 100–200, green = 50–100, blue =< 50 and grey = n/a. Data from WHO, 2006

Page 5: Pulmonary tuberculosis DR. Yousef Noaimat MD.FCCP Consultant in pulmonary and internal medicine

Reason for increase incidence

• HIV infections and the neglect of TB control programs

• drug-resistant : from 2000 to 2004, 20% of TB cases being resistant to standard treatments and 2% resistant to second-line drugs

• Lack of access to health care

• Poverty

Page 6: Pulmonary tuberculosis DR. Yousef Noaimat MD.FCCP Consultant in pulmonary and internal medicine

• Definition :Pulmonary tuberculosis (TB) is a contagious bacterial infection that mainly involves the lungs, but may spread to other organs caused by the Mycobacterium tuberculosis and Mycobacterium bovis

• In the United States, most people will recover from primary TB infection without further evidence of the disease. The infection may stay non active for years and then reactivate.

• Most people who develop symptoms of a TB infection first became infected in the past. However, in some cases, the disease may become active within weeks after the primary infection

Page 7: Pulmonary tuberculosis DR. Yousef Noaimat MD.FCCP Consultant in pulmonary and internal medicine

Transmission

• cough, sneeze, speak, they expel infectious aerosol droplets 0.5 to 5 µm in diameter. A single sneeze can release up to 40,000 droplets.Each one of these droplets may transmit the disease, since the infectious dose of tuberculosis is very low and the inhalation of just a single bacterium can cause a new infection

• Transmission can only occur from people with active — not latent 

Page 8: Pulmonary tuberculosis DR. Yousef Noaimat MD.FCCP Consultant in pulmonary and internal medicine

• When the disease becomes active, 75% of the cases are pulmonary TB

• the other 25% of active cases, the infection moves from the lungs, causing other kinds of TB

Page 9: Pulmonary tuberculosis DR. Yousef Noaimat MD.FCCP Consultant in pulmonary and internal medicine

Clinical presentation

The primary stage of the disease usually doesn't have symptoms. When symptoms do occur, they may include:

• Cough heamoptysis• Excessive sweating, especially at night • Fatigue • Fever • Unintentional weight loss Other symptoms that may occur with this disease:• Breathing difficulty • Chest pain • Wheezing

Page 10: Pulmonary tuberculosis DR. Yousef Noaimat MD.FCCP Consultant in pulmonary and internal medicine

Examination

• Examination may show:

• Clubbing of the fingers or toes (in people with advanced disease)

• Enlarged or tender lymph nodes in the neck or other areas

• Fluid around a lung

• Unusual breath sounds (crackles)

Page 11: Pulmonary tuberculosis DR. Yousef Noaimat MD.FCCP Consultant in pulmonary and internal medicine

Diagnosis • Sputum examination and cultures (ZN STAIN)

how can I take a good sample?

• Chest x-ray • Chest CT scan• Bronchoscopy• tuberculin skin test • Gastric aspiration?• The main problem with tuberculosis diagnosis is the difficulty in

culturing this slow-growing organism in the laboratory (it may take 4 to 12 weeks for blood or sputum culture

Page 12: Pulmonary tuberculosis DR. Yousef Noaimat MD.FCCP Consultant in pulmonary and internal medicine
Page 13: Pulmonary tuberculosis DR. Yousef Noaimat MD.FCCP Consultant in pulmonary and internal medicine

Mantoux tuberculin skin test

Page 14: Pulmonary tuberculosis DR. Yousef Noaimat MD.FCCP Consultant in pulmonary and internal medicine

• polymerase chain reaction detection of bacterial DNA, and assays to detect the release of interferon gamma in response to mycobacterial proteins such as ESAT These are not affected by immunization or environmental mycobacteria, so generate fewer false positive results

Page 15: Pulmonary tuberculosis DR. Yousef Noaimat MD.FCCP Consultant in pulmonary and internal medicine

Treatment

• Latent TB treatment usually uses a single antibiotic • People with latent infections are treated to prevent them

from progressing to active TB disease later in life. However, treatment using Rifampicin and Pyrazinamide is not risk-free. The Centers for Disease Control and Prevention (CDC) notified healthcare professionals of revised recommendations against the use of rifampin plus pyrazinamide for treatment of latent tuberculosis infection, due to high rates of hospitalization and death from liver injury associated with the combined use of these drugs

Page 16: Pulmonary tuberculosis DR. Yousef Noaimat MD.FCCP Consultant in pulmonary and internal medicine

Treatment

• while active TB disease is best treated with combinations of several antibiotics, to reduce the risk of the bacteria developing antibiotic resistance

• The two antibiotics most commonly used are rifampicin and isoniazid

Page 17: Pulmonary tuberculosis DR. Yousef Noaimat MD.FCCP Consultant in pulmonary and internal medicine

Treatment

• Initial phase 8 WKS:

• rifampicin +isoniazid +PYRAZINAMIDE

• If resistant possible add ethmbutol or sterptomycin

• Give pyridoxine throughout treatment

• Continuation phase (4month)

• rifampicin +isoniazid+ pyridoxine

Page 18: Pulmonary tuberculosis DR. Yousef Noaimat MD.FCCP Consultant in pulmonary and internal medicine

Treatment

When can I say treatment failure?

Page 19: Pulmonary tuberculosis DR. Yousef Noaimat MD.FCCP Consultant in pulmonary and internal medicine

• Treatment failure is defined by

• + culture after 3 months

• +AFB stain after 5 months

• And should be treated by adding 2 more drug

Page 20: Pulmonary tuberculosis DR. Yousef Noaimat MD.FCCP Consultant in pulmonary and internal medicine

Treatment

• Main side effect

• Rifampicin: hepatitis (small raise of ASTis acceptable . Stop if biliurubin raise)

• Isoniazid: hepatitis. Neuropathy

• ethmbutol: optic neuropathy

• PYRAZINAMIDE: hepatitis

(contraindicted in gout)

Page 21: Pulmonary tuberculosis DR. Yousef Noaimat MD.FCCP Consultant in pulmonary and internal medicine

Prevention

• identified people with TB and their contacts are and then treated

• children are vaccinated to protect them from TB. Unfortunately, no vaccine is available that provides reliable protection for adults

Page 22: Pulmonary tuberculosis DR. Yousef Noaimat MD.FCCP Consultant in pulmonary and internal medicine

Thank you